Abstract: Trienamide and tetraenamide compounds, and pharmaceutically-acceptable salts thereof, of the formula: ##STR1## wherein R is a straight or branched chain tri-unsaturated or tetra-unsaturated fatty acid amide having from 14 to 24 carbon atoms, exhibit anit-inflammatory and analgesic activity when administered to humans or lower animals.

Abstract: The present invention involves certain 2-(5-phenyl-2-furanyl)-imidazoles, pharmaceutical compositions containing such compounds, and methods for enhancing the contractile force of cardiac muscle of a mammal which comprises systemically administering such compounds to a mammal.

Abstract: The present invention relates to methods for treating or preventing dental plaque, caries, or gingival or periodontal diseases of the oral cavity in humans or lower animals, with reduced staining of teeth or dentures. The methods comprise topically applying to the oral surfaces of the teeth or dentures of the humans or lower animals:(a) a safe and effective amount of a monoperoxyphthalate compound, and(b) a safe and effective amount of an anti-plaque bis-biguanide compound.The present invention also relates to compositions for achieving such treatments.

Abstract: The invention relates to androstane-17-carboxylic acid esters, represented by general formula (I): ##STR1## wherein R.sub.1 represents a lower alkyl group containing 1 to 4 carbon atoms, a lower alkyl group containing 2 to 4 carbon atoms substituted by an amino group, or an aralkyl group from 6 to 12 carbon atoms, R.sub.2 and R.sub.3, which may be the same or different, represent a hydrogen atom or a lower alkyl group containing 1 to 4 carbon atoms, R.sub.4 represents a hydrogen atom, a hydroxy group or an acetoxy group, R.sub.5 represents a hydroxy or acetoxy group, or R.sub.4 and R.sub.5 represent together a divalent alkylenedioxy group, R.sub.6 represents a hydroxy group, a methoxy group, or an acetoxy group, R.sub.7 represents a methyl group or a hydroxymethyl group, R.sub.8 represents an hydrogen atom or a hydroxy group and ##STR2## represents either a ##STR3## group or a ##STR4## carbon atom having the double linkage in the 4- or 5-position of the steroid nucleus.

Abstract: The present invention involves certain N-hydroxy-5-phenyl-2-furancarboximidamides, pharmaceutical compositions containing such compounds, and methods for increasing the contractile force of cardiac muscle of a mammal which comprises systemically administering such compounds to a mammal.

Abstract: Disclosed are pharmaceutical compositions comprising sorbohydroxamic acid, or pharmaceutically-acceptable salts thereof, which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of sorbohydroxamic acid together with tocopherol sorbate and/or sunscreens are also disclosed.Also disclosed is a method for using these compositions topically, prior to UV exposure, to prevent damage to skin caused by acute or chronic UV exposure.

Abstract: The present invention relates to novel compounds having nitrogen-containing, saturated bicyclic cyclopentane-fused rings which are geminally disubstituted with phosphonate groups. Most preferred compounds of the present invention have the general structure: ##STR1## The present invention further relates to pharmaceutical compositions containing these novel compounds. Finally, this invention relates to methods for treating or preventing diseases characterized by abnormal calcium and phosphate metabolism by utilizing a compound or pharmaceutical composition of the present invention.

Abstract: The invention involves a method for treating or preventing a malignant hyperthermic reaction in a human or lower animal by administering a safe and effective amount of azumolene.

Abstract: The present invention involves compounds having the structure: ##STR1## (a) --A-- is selected from the group consisting of ##STR2## (b) --Y is selected from certain low molecular weight moieties which terminate in specific functional groups: --C.tbd.CH, ##STR3## and aldehydes in the form of their acetals; pharmaceutical compositions comprising such compounds; and methods for treating inflammation by administering such compounds.

Abstract: The present invention relates to oral compositions, such as dentrifices, toothpastes and mounthwashes, which provide an anticalculus benefit. These compositions comprise a safe and effective amount of an anticalculus agent which is a polyepoxysuccinic acid, or its pharmaceutically-acceptable salts, along with a pharmaceutically-acceptable carrier. The present invention also relates to a method for inhibiting or reducing the development of dental calculus by contacting the oral cavity with a safe and effective amount of an anticalculus agent which is a polyepoxysuccinic acid, or its pharmaceutically-acceptable salt.

Abstract: Disclosed are pharmaceutical compositions comprising tocopherol sorbate which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of tocopherol sorbate and sunscreening agents are also disclosed.Also disclosed is a method for using these compositions topically, to prevent damage to skin caused by acute or chronic UV exposure.

Abstract: Disclosed are pharmaceutical compositions comprising tocopherol sorbate and an anti-inflammatory agent which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of tocopherol sorbate, an anti-inflammatory agent, and a sunscreen are also disclosed.Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.

Abstract: The present invention involves compounds having the structure: ##STR1## wherein: (a) --A.sup.1 is selected from the group consisting of --OH, --H, and --O.sub.2 CR;(b) --A.sup.2 is selected from the group consisting of unsubstituted or substituted, saturated or unsaturated, straight, branched and cyclic alkyl having from 1 to about 10 carbon atoms;(c)--A.sup.3 is selected from --C(CH.sub.3).sub.3, --Si(CH.sub.3).sub.3, and --CF.sub.3 ; and(d) --Y is selected from certain low molecular weight alkyl chains which terminate in specific unsaturated functional groups: ##STR2## and aldehydes in the form of their acetals; pharmaceutical compositions comprising such compounds; and methods for treating inflammation by administering such compounds.

Abstract: Disclosed are pharmaceutical compositions comprising sorbohydroxamic acid, or pharmaceutically-acceptable salts thereof, and an anti-inflammatory agent, which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of sorbohydroxamic acid and an anti-inflammatory agent together with tocopherol sorbate and/or sunscreens are also disclosed.Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.

Abstract: Diphosphonate-derivatized macromolecules, such as proteins, suitable for use as technetium-99m-based scanning agents and as anticalcification agents are disclosed. The scanning agents are prepared by combining Tc-99m in a +3, +4 and/or +5 oxidation state with the diphosphonate-derivatized macromolecules. Also disclosed are pharmaceutical compositions containing these diphosphonate-derivatized macromolecules and methods for scintigraphic imaging using these diphosphonate-derivatized macromolecules labeled with Tc-99m.

Abstract: A method for treating or preventing osteoporosis is disclosed. Bone cells are synchronized during a bone cell activating period; bone resorption, which normally follows activation, is inhibited using a polyphosphonate; bone formation is allowed to occur in the rest period during which nutrient supplements may be administered to the patient. The method shortens the natural cycle time of bone formation/resorption, resulting in a faster bone build-up.

Abstract: The invention involves a method for achieving systemic administration of azumolene by delivering the drug to the intestines without exposing the drug in the stomach, and pharmaceutical compositions for achieving such administration of azumolene.

Abstract: A kit for use in the treatment of osteoporosis is disclosed. The kit comprises a bone cell activating compound, a bone resorption inhibiting polyphosphonate, and a nutrient supplement or placebo, for sequential administration.

Abstract: An analgesic composition comprising capsaicin or a capsaicin analogue and an analgesic selected from the class of non-steroidal anti-inflammatory, antipyretic and analgesic drugs is disclosed. This combination has been found to exhibit unexpectedly enhanced analgesic activity in humans and lower animals without a corresponding increase in undesirable side effects.

Abstract: A method for treating or preventing osteoporosis is disclosed. Bone cells are synchronized during a bone cell activating period; bone resorption, which normally follows activation, is inhibited using a polyphosphonate; bone formation is allowed to occur in the rest period during which nutrient supplements may be administered to the patient.